Comparative analysis of NX-2127 and ibrutinib in treating B-cell malignancies

Oncology is an ever-changing field of medicine with the constant development of innovative treatments. Small-molecule drugs have entered the spotlight in the past few decades for their efficacy, selectivity, and ability to target intracellular proteins. Small-molecule inhibitors (SMIs) are small-molecule drugs that inhibit proteins involved in tumour growth [1,2]. Proteolysis targeting chimeras (PROTACs) are heterobifunctional molecules that degrade proteins involved in tumour growth [3,4]. Both treatments have revolutionized the field of oncology as they have proven to be more beneficial than traditional treatments.